NLS Pharmaceutics AG

Equities

NLSP

CH0523961370

Biotechnology & Medical Research

Market Closed - Nasdaq 16:30:00 2024-05-31 EDT 5-day change 1st Jan Change
0.141 USD -15.16% Intraday chart for NLS Pharmaceutics AG -18.97% -76.10%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
NLS Pharmaceutics Ltd. Enters into Additional Bridge Loan Addendums, or the Second Bridge Loan Addendums CI
NLS Pharmaceutics Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Nls Pharmaceutics Ltd. Announces Resignation of Anthony S. Walsh as A Member of the Board of Directors CI
NLS Pharmaceutics Ltd. announced that it has received $1.75 million in funding CI
NLS Pharmaceutics Ltd. announced that it expects to receive $1.75 million in funding CI
NLS Pharmaceutics Files Plan to Regain Nasdaq Listing Compliance MT
NLS Pharmaceutics AG Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Sector Update: Health Care Stocks Rise in Late Afternoon Trading MT
Sector Update: Health Care Stocks Rise in Afternoon Trading MT
Top Midday Gainers MT
NLS Pharmaceutics Signs Option Agreement to Acquire Rights to Aexon Labs' Assets; Shares Rise MT
NLS Pharmaceutics Announces Exploration of Strategic Alternatives to Maximize Shareholder Value CI
Maxim Downgrades NLS Pharmaceutics to Hold From Buy MT
Top Premarket Gainers MT
NLS Pharmaceutics Ltd. cancelled the transaction announced on August 19, 2022 CI
Sector Update: Health Care Stocks Steady Pre-Bell Monday MT
NLS Pharmaceutics' Mazindol ER Trial to Move to Phase 3 MT
NLS Pharmaceutics to Proceed with Phase 3 Clinical Program for Mazindol ER for the Treatment of Narcolepsy Following FDA Review and IRB Approval of the Full Study Protocol CI
NLS Pharmaceutics Ltd. Approves Board Appointments CI
NLS Pharmaceutics Says Drug Interaction Studies of Mazindol Show 'Positive Results' MT
NLS Pharmaceutics Announces Positive Safety Data From In Vitro CYP450 and Transporter Mediated Drug-Drug Interaction Studies of Mazindol CI
NLS Pharmaceutics AG Announces Executive Changes CI
NLS Pharmaceutics Appoints Keith Harrison Dewedoff as Interim Chief Financial Officer CI
NLS Pharmaceutics Ltd. Announces the Resignation of Chad Hellmann as Chief Financial Officer CI
NLS Pharmaceutics AG Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Chart NLS Pharmaceutics AG
More charts
NLS Pharmaceutics AG, formerly NLS 1 Pharma AG, is a Switzerland-based company that operates as a biopharmaceutical company. The Company focuses on development of medicines for neurobehavioral and neurocognitive disorders treatment. The Company serves customers worldwide.
More about the company
  1. Stock Market
  2. Equities
  3. NLSP Stock
  4. News NLS Pharmaceutics AG
  5. NLS Pharmaceutics : Brookline Capital Initiates Coverage on NLS Pharmaceutics AG With Buy Rating, $12 Price Target